Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)
Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett Syndrome
Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results And Provides Clinical Study Updates
Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019
Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics – ASENT 2019 Annual Meeting
Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S.
Anavex Life Sciences Reaches 50% Enrollment Threshold in ANAVEX®2-73 Parkinson’s Disease Dementia (PDD) Phase 2 Study Ahead of Schedule
